Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial
Circulation: Cardiovascular Interventions · 2023
DOI: 10.1161/circinterventions.122.012867 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2023. Verfasst von Zardasht Oqab und 18 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Diabetes Mellitus, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: CIHR.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: In the COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strategy of complete revascularization reduced the risk of major cardiovascular events compared with culprit-lesion-only percutaneous coronary intervention in patients presenting with ST-segment–elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Patients with diabetes have a worse prognosis following STEMI. We evaluated the consistency of the effects of complete revascularization in patients with and without diabetes. METHODS: The COMPLETE trial randomized a strategy of complete revascularization, consisting of angiography-guided percutaneous coronary intervention of all suitable nonculprit lesions, versus a strategy of culprit-lesion-only percutaneous coronary intervention (guideline-directed medical therapy alone). In prespecified analyses, treatment effects were determined in patients with and without diabetes on the first coprimary outcome of cardiovascular death or new myocardial infarction and the second coprimary outcome of cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. Interaction P values were calculated to evaluate whether there was a differential treatment effect in patients with and without diabetes. RESULTS: Of the 4041 patients enrolled in the COMPLETE trial, 787 patients (19.5%) had diabetes. The median HbA1c (glycated hemoglobin) was 7.7% in the diabetes group and 5.7% in the nondiabetes group. Complete revascularization consistently reduced the first coprimary outcome in patients with diabetes (hazard ratio, 0.87 [95% CI, 0.59–1.29]) and without diabetes (hazard ratio, 0.70 [95% CI, 0.55–0.90]), with no evidence of a differential treatment effect (interaction P =0.36). Similarly, for the second coprimary outcome, no differential treatment effect (interaction P =0.27) of complete revascularization was found in patients with diabetes (hazard ratio, 0.61 [95% CI, 0.43–0.87]) and without diabetes (hazard ratio, 0.48 [95% CI, 0.39–0.60]). CONCLUSIONS: Among patients presenting with STEMI and multivessel disease, the benefit of complete revascularization over a culprit-lesion-only percutaneous coronary intervention strategy was consistent regardless of the presence or absence of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Population Health Research Institute, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.).
- McMaster University, Hamilton, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.).
- Hamilton Health Sciences, Ontario, Canada (Z.O., N.P.-E., T.M., M.S., N.V., S.R.M.).
- Dalhousie University, Nova Scotia, Halifax, Canada (Z.O.).
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom (V.K.).
- Centre for Cardiovascular Innovation, UBC Division of Cardiology, St Paul's and Vancouver General Hospital, Canada (D.A.W., R.H.B., J.A.C.).
ORCID-Profile: Vijay Kunadian, David A Wood, Robert F Storey, Sunil V Rao, Roxana Mehran, Natalia Pinilla-Echeverri, Thenmozhi Mani, Matthias Bossard, Matthew Sibbald, Philippe Gabriel Steg, John A Cairns, Shamir R Mehta
Förderung
- CIHR
Zitieren
APA
Oqab, Z., Kunadian, V., Wood, D. A., Storey, R. F., Rao, S. V., Mehran, R., Pinilla-Echeverri, N., Mani, T., Boone, R. H., Kassam, S., Bossard, M., Mansour, S., Ball, W., Sibbald, M., Valettas, N., Moreno, R., Steg, P. G., Cairns, J. A., & Mehta, S. R. (2023). Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.122.012867
Vancouver
Oqab Z, Kunadian V, Wood DA, Storey RF, Rao SV, Mehran R, et al. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial. Circulation: Cardiovascular Interventions. 2023. doi:10.1161/circinterventions.122.012867
BibTeX
@article{Oqab2023,
author = {Oqab, Zardasht and Kunadian, Vijay and Wood, David A and Storey, Robert F and Rao, Sunil V and Mehran, Roxana and Pinilla-Echeverri, Natalia and Mani, Thenmozhi and Boone, Robert H and Kassam, Saleem and Bossard, Matthias and Mansour, Samer and Ball, Warren and Sibbald, Matthew and Valettas, Nicholas and Moreno, Raul and Steg, Philippe Gabriel and Cairns, John A and Mehta, Shamir R},
title = {Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2023},
doi = {10.1161/circinterventions.122.012867}
}
EUVIMED